DE60312333D1 - Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung - Google Patents

Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung

Info

Publication number
DE60312333D1
DE60312333D1 DE60312333T DE60312333T DE60312333D1 DE 60312333 D1 DE60312333 D1 DE 60312333D1 DE 60312333 T DE60312333 T DE 60312333T DE 60312333 T DE60312333 T DE 60312333T DE 60312333 D1 DE60312333 D1 DE 60312333D1
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
solid pharmaceutical
production
composition containing
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60312333T
Other languages
English (en)
Other versions
DE60312333T2 (de
Inventor
Chacra-Vernet Marie-Line Abou
Noel Zakarian
Dominique Toselli
Rene Gimet
Claude Laruelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CLL Pharma SA
Original Assignee
CLL Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CLL Pharma SA filed Critical CLL Pharma SA
Application granted granted Critical
Publication of DE60312333D1 publication Critical patent/DE60312333D1/de
Publication of DE60312333T2 publication Critical patent/DE60312333T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60312333T 2002-06-25 2003-06-24 Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung Expired - Fee Related DE60312333T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0207831 2002-06-25
FR0207831A FR2841138B1 (fr) 2002-06-25 2002-06-25 Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
PCT/FR2003/001933 WO2004000279A1 (fr) 2002-06-25 2003-06-24 Composition pharmaceutique solide contenant un principe actif lipophile, son procédé de préparation

Publications (2)

Publication Number Publication Date
DE60312333D1 true DE60312333D1 (de) 2007-04-19
DE60312333T2 DE60312333T2 (de) 2007-12-20

Family

ID=29720010

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60312333T Expired - Fee Related DE60312333T2 (de) 2002-06-25 2003-06-24 Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung

Country Status (12)

Country Link
US (1) US20080095838A1 (de)
EP (1) EP1521574B1 (de)
JP (1) JP2005533802A (de)
KR (1) KR20050040869A (de)
AT (1) ATE355829T1 (de)
AU (1) AU2003260621A1 (de)
CA (1) CA2490341A1 (de)
DE (1) DE60312333T2 (de)
ES (1) ES2283821T3 (de)
FR (1) FR2841138B1 (de)
WO (1) WO2004000279A1 (de)
ZA (1) ZA200500716B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
CN101389315A (zh) * 2004-06-17 2009-03-18 莫茨药物股份两合公司 美金刚口服剂型即释制剂
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
EP1830830A4 (de) * 2004-12-06 2010-02-10 Reliant Pharmaceuticals Inc Omega-3-fettsäuren und dyslipidämisches mittel für die lipidtherapie
CA2608690C (en) 2005-05-18 2016-07-05 Dainippon Sumitomo Pharma Co., Ltd. Stable tablet containing droxidopa
US20070238746A1 (en) 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US20090074872A1 (en) * 2006-06-26 2009-03-19 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
AU2007265452A1 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
CA2664641A1 (en) 2006-09-26 2008-04-10 Astellas Pharma, Inc. Controlled release dosage form of tacrolimus
CA2674039A1 (en) * 2006-12-28 2008-07-17 Astellas Pharma Inc. Sustained release formulation for tacrolimus
WO2009140341A2 (en) * 2008-05-13 2009-11-19 Dr. Reddy's Laboratories Ltd. Atorvastatin compositions
JP5583012B2 (ja) * 2008-06-13 2014-09-03 大日本住友製薬株式会社 口腔内速崩壊錠及びその製造方法
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
JP5953646B2 (ja) * 2009-11-24 2016-07-20 大正製薬株式会社 イブプロフェン含有固形製剤
JP5508311B2 (ja) * 2011-02-28 2014-05-28 テバ ファーマシューティカル インダストリーズ リミティド 低水溶性薬物とともに使用することによく適した圧縮固体状投与形態の製造方法およびそれにより製造された圧縮固体状投与形態
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2902029B1 (de) 2012-09-25 2018-08-08 Chugai Seiyaku Kabushiki Kaisha Ret-inhibitor
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
CA2946518C (en) 2014-04-25 2022-07-26 Chugai Seiyaku Kabushiki Kaisha Preparation containing tetracyclic compound at high dose
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112017013982A2 (pt) 2015-01-16 2018-01-02 Chugai Seiyaku Kabushiki Kaisha fármaco de combinação
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. ステロイドホルモン薬学的組成物
WO2019034712A1 (en) 2017-08-17 2019-02-21 F. Hoffmann-La Roche Ag NOVEL PHARMACEUTICAL COMPOSITIONS FOR BASIC OR NEUTRAL COMPOUNDS OF LOW MOLECULAR WEIGHT
WO2019063478A1 (en) * 2017-09-26 2019-04-04 Capsugel Belgium Nv SUB-MICRONIC PARTICLE FORMULATIONS
WO2020050241A1 (ja) 2018-09-04 2020-03-12 中外製薬株式会社 4環性化合物の製造方法
CN114569605A (zh) * 2022-03-10 2022-06-03 沈阳药科大学 阿托伐他汀-黄酮类化合物共无定型复合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0729926B2 (ja) * 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物
TW209174B (de) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
JP3696087B2 (ja) * 1997-12-31 2005-09-14 チョンワエ ファーマ コーポレーション イトラコナゾール(itraconazole)経口用製剤及びその製造方法
AU3074700A (en) * 1999-01-22 2000-08-07 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with improved oral absorption
US6465011B2 (en) * 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
KR100863146B1 (ko) * 2000-07-17 2008-10-14 아스텔라스세이야쿠 가부시키가이샤 경구 흡수 개선 의약 조성물

Also Published As

Publication number Publication date
JP2005533802A (ja) 2005-11-10
FR2841138A1 (fr) 2003-12-26
FR2841138B1 (fr) 2005-02-25
ATE355829T1 (de) 2007-03-15
KR20050040869A (ko) 2005-05-03
AU2003260621A1 (en) 2004-01-06
US20080095838A1 (en) 2008-04-24
EP1521574B1 (de) 2007-03-07
WO2004000279A1 (fr) 2003-12-31
CA2490341A1 (fr) 2003-12-31
EP1521574A1 (de) 2005-04-13
DE60312333T2 (de) 2007-12-20
ES2283821T3 (es) 2007-11-01
ZA200500716B (en) 2006-09-27

Similar Documents

Publication Publication Date Title
DE60312333D1 (de) Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung
WO2003090726A3 (en) Chewable soft capsule
BR9503386A (pt) Formulaçao farmacêutica comprimido dispersivel e processo para a fabricaçao de comprimidos dispersíveis contendo cloridrato de fluoxetina
WO2004032862A3 (en) Cyclodextrin-based materials, compositions and uses related thereto
EP1428821A8 (de) Piperidin-4-ylamine mit analgetischer Wirksamkeit
BRPI0412975A (pt) espuma penetrante para uso farmacêutico
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
HUP0004924A2 (hu) Ciklodextrineket tartalmazó gyógyászati készítmények
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
CA2396159A1 (en) Novel substituted benzimidazole dosage forms and method of using same
BR0103033A (pt) Partìculas farmacêuticas de sabor mascarado
HUP0302086A2 (hu) Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására
FR2811552B1 (fr) Composition notamment cosmetique ou pharmaceutique se presentant sous forme solide
ATE307569T1 (de) Gelierbare pharmazeutische zusammensetzungen
DE60001546D1 (de) Liponsaürederivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
WO2003043631A3 (en) Method for identification of tumor targeting enzymes
EE9900589A (et) Farmatseutilised kompositsioonid limaskestale kandmiseks
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
ATE326264T1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
DE60019334D1 (de) Antivirale arznei
DE50004443D1 (de) Wirkstoffhaltige komposition sowie deren herstellung und verwendung
BR9913135A (pt) Formulação oral

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee